The price of Gilead Sciences, Inc (NASDAQ:GILD) shares last traded on Wall Street rose 1.52% to $92.38.
GILD stock price is now 0.59% away from the 50-day moving average and 17.92% away from the 200-day moving average. The market capitalization of the company currently stands at $115.13B.
With the price target enhanced from $87 to $113, Morgan Stanley Upgraded its rating from Equal-Weight to Overweight for Gilead Sciences, Inc (NASDAQ: GILD). , while ‘Wolfe Research’ rates the stock as ‘Outperform’
In other news, ANDREW DICKINSON, Officer bought 2,500 shares of the company’s stock on Jan 15 ’25. The stock was bought for $228,375 at an average price of $91.35. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 19 ’24, 10% Owner GILEAD SCIENCES, INC. bought 940,499 shares of the business’s stock. A total of $20,098,464 was incurred on buying the stock at an average price of $21.37. This leaves the insider owning 2,209,471 shares of the company worth $204.11 million. A total of 0.10% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $62.07 and a high of $98.90. As of last week, the company has a debt-to-equity ratio of 1.26, a current ratio of 1.26, and a quick ratio of 1.10. According to the stock market information, the enterprise value for the company is $131598041088, which is based on a 1041.49 price-to-earnings ratio, a 111.29 price-to-earnings-growth ratio, and a beta of 0.20. The fifty day moving average price for GILD is $91.7684 and a two-hundred day moving average price translates $78.2429 for the stock.
The latest earnings results from Gilead Sciences, Inc (NASDAQ: GILD) was released for 2024-09-30. The net profit margin was 0.45% and return on equity was 0.62% for GILD. The company reported revenue of $7.54 billion for the quarter, compared to $7.05 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.01 percent.
